A robust pipeline targets major endocrine diseases, with PALSONIFY showing strong launch metrics and clinical efficacy in acromegaly. Atumelnant and CRN09682 advance in late-stage trials for CAH, Cushing's, and neuroendocrine tumors. $1.3B cash funds operations into 2030.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.